DAVID K. HENDERSON, M.D.; ALFRED J. SAAH, M.D., M.P.H.; BARBARA J. ZAK, B.S.N.; RICHARD A. KASLOW, M.D., M.P.H.; H. CLIFFORD LANE, M.D.; THOMAS FOLKS, Ph.D.; WILLIAM C. BLACKWELDER, Ph.D.; JAMES SCHMITT, M.D.; DEBORAH J. LaCAMERA, B.S.N.; HENRY MASUR, M.D.; ANTHONY S. FAUCI, M.D.
To assess the risk of nosocomial transmission of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV), we prospectively evaluated a cohort of 531 health care workers. One hundred fifty of these employees reported percutaneous or mucous membrane exposures to blood or body fluids from a patient with the acquired immunodeficiency syndrome (AIDS) during the treatment of 238 such patients since 1981. None of these 150 employees had serologic evidence of HTLV-III/LAV infection on follow-up from 6 to 46 months after exposure. Of the 150, 46 were studied immunologically and 29 had lymphocytes cultured for HTLV-III/LAV. Results of all studies were normal. Of the 531 employees, 3 (0.56%) had serologic evidence of HTLV-III/LAV infection. All were seropositive at the time of study entry; none reported adverse nosocomial exposures. All acknowledged membership in one or more established risk groups for AIDS. This study provides strong evidence that the risk of nosocomial transmission of HTLV-III/LAV is extremely low.
HENDERSON DK, SAAH AJ, ZAK BJ, et al. Risk of Nosocomial Infection with Human T-Cell Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in a Large Cohort of Intensively Exposed Health Care Workers. Ann Intern Med. 1986;104:644–647. doi: 10.7326/0003-4819-104-5-644
Download citation file:
Published: Ann Intern Med. 1986;104(5):644-647.
HIV, Hospital Medicine, Hospital-Acquired Infections, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use